Viromed Medical AG is reporting positive results for its PulmoPlas therapy in the treatment of ventilator-associated pneumonia (VAP) in intensive care unit patients.
PulmoPlas is an investigational device that uses cold atmospheric plasma to target and destroy viruses and bacteria in the respiratory tract in 30-90 seconds, according to Viromed.
According to the company, treatment with PulmoPlas destroys bacteria in the upper and lower airways, including the lower alveoli, in 30-90 seconds (in MRSA bacteria). The procedure is characterized by a high degree of tolerability, without any harmful effects on the respiratory epithelia (bronchial and alveolar), Viromed reports.
“The results of our clinical trial have far exceeded our expectations in terms of efficacy and safety. Based on the available data, we are convinced that PulmoPlas therapy will revolutionize pneumonia treatment worldwide,” said Uwe Perbandt, CEO of Viromed Medical AG. “Our innovative procedure has the potential to save lives and significantly shorten hospital stays, and thus could benefit all hospitals with ICUs. As the only company in the world that can offer such a treatment, we are aware of our responsibility and will work vigorously to make PulmoPlas available to hospitals as quickly as possible.”
The company says the study results are expected to be published in early summer 2025, and the therapy will be validated via a second procedure. Based on the study results, Viromed plans to submit an application to the Federal Institute for Drugs and Medical Devices (BfArM) for marketing authorization of PulmoPlas as a medical device for the treatment of VAP.
More information is available on the Viromed website.
